Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare to Supply CytoGenix With DNA Production Reagents Exclusively for Compound Manufacturing

This update serves to clarify the fact that GE has licensed its production reagents exclusively to CytoGenix for the company to use in compound manufacturing.


NEW YORK, March 23 (GenomeWeb News) - GE Healthcare will exclusively provide its DNA production reagents to CytoGenix where the intended application is the manufacture of therapeutic compounds, CytoGenix said today in a statement.


A CytoGenix spokesperson said other labs or companies can license the reagents for purposes other than compound manufacturing.


The companies did not disclose financial terms of the agreement.


Houston, Tex.-based CytoGenix manufactures DNA-based vaccines and therapeutics for infectious diseases, inflammatory disorders, and cancer.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.